PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10643176-3	1999	Preclinical studies of celecoxib in vitro and in vivo support the COX-2 hypothesis that the therapeutic effects of NSAIDs are due to the inhibition of COX-2, and the adverse events associated with NSAID therapy are due to the inhibition of cyclooxygenase-1 (COX-1), the constitutively expressed isoform of COX.	Celecoxib	23-32	prostaglandin-endoperoxide synthase 1	Homo sapiens	240-256	
12910047-1	2003	Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) which acts via specific inhibition of cyclooxygenase-2 (synthesis of prostaglandins mediating pathological inflammation) but which preserves the homeostatic action of cyclooxygenase-1.	Celecoxib	0-9	prostaglandin-endoperoxide synthase 1	Homo sapiens	227-243	
10664917-2	2000	Celecoxib, an antiarthritic agent that inhibits COX-2 but spares COX-1 at therapeutic doses, is expected to have minimal effects on platelet function.	Celecoxib	0-9	prostaglandin-endoperoxide synthase 1	Homo sapiens	65-70	
15943176-1	2005	The aim of this study was to compare the in vivo effects on free radical metabolism of 2 non-steroidal anti-inflammatory drugs (NSAIDs): tenoxicam, an oxicam preferentially cyclooxygenase-1 (COX-1) inhibitor, and celecoxib, a sulfonamide selective COX-2 inhibitor.	Celecoxib	213-222	prostaglandin-endoperoxide synthase 1	Homo sapiens	191-196	
12664569-3	2002	Recently, a specific cyclooxygenase-2 (COX-2) inhibitor, Celecoxib, was developed, which inhibits COX-2-induced inflammation without inhibiting the cytoprotective function of cyclooxygenase-1 (COX-1).	Celecoxib	57-66	prostaglandin-endoperoxide synthase 1	Homo sapiens	193-198	
11060900-4	2000	Recently, a specific COX-2 inhibitor, Celecoxib, was developed, which inhibits COX-2-induced inflammation without inhibiting the cytoprotective function of cyclooxygenase-1 (COX-1).	Celecoxib	38-47	prostaglandin-endoperoxide synthase 1	Homo sapiens	174-179	
10643176-3	1999	Preclinical studies of celecoxib in vitro and in vivo support the COX-2 hypothesis that the therapeutic effects of NSAIDs are due to the inhibition of COX-2, and the adverse events associated with NSAID therapy are due to the inhibition of cyclooxygenase-1 (COX-1), the constitutively expressed isoform of COX.	Celecoxib	23-32	prostaglandin-endoperoxide synthase 1	Homo sapiens	258-263	
34471051-0	2021	Synthesis and Biological Evaluation of Salicylic Acid Analogues of Celecoxib as a New Class of Selective Cyclooxygenase-1 Inhibitor.	Celecoxib	67-76	prostaglandin-endoperoxide synthase 1	Homo sapiens	105-121	
10193998-2	1999	This is possible because celecoxib is a cyclooxygenase-2 (COX-2)-specific inhibiting agent that inhibits the conversion of arachidonic acid to the prostaglandins that mediate pain and inflammation while having no effect on the formation of the prostaglandins that mediate normal homeostasis in the gastrointestinal tract, kidneys, and platelets and that are formed under the control of cyclooxygenase-1 (COX-1).	Celecoxib	25-34	prostaglandin-endoperoxide synthase 1	Homo sapiens	386-402	
10193998-2	1999	This is possible because celecoxib is a cyclooxygenase-2 (COX-2)-specific inhibiting agent that inhibits the conversion of arachidonic acid to the prostaglandins that mediate pain and inflammation while having no effect on the formation of the prostaglandins that mediate normal homeostasis in the gastrointestinal tract, kidneys, and platelets and that are formed under the control of cyclooxygenase-1 (COX-1).	Celecoxib	25-34	prostaglandin-endoperoxide synthase 1	Homo sapiens	404-409	
26379884-8	2015	PTGS1, PTGS2, ADAMTS5, PTGER2, mPTGES and PTGER4 were among the genes down-regulated upon the treatment with celecoxib.	Celecoxib	109-118	prostaglandin-endoperoxide synthase 1	Homo sapiens	0-5	
25385584-2	2014	We sought to quantitate precisely the propensity of commonly consumed NSAIDs:ibuprofen, naproxen, and celecoxib:to cause a drug-drug interaction with aspirin in vivo by measuring the target engagement of aspirin directly by MS. We developed a novel assay of cyclooxygenase-1 (COX-1) acetylation in platelets isolated from volunteers who were administered aspirin and used conventional and microfluidic assays to evaluate platelet function.	Celecoxib	102-111	prostaglandin-endoperoxide synthase 1	Homo sapiens	258-274	
25385584-2	2014	We sought to quantitate precisely the propensity of commonly consumed NSAIDs:ibuprofen, naproxen, and celecoxib:to cause a drug-drug interaction with aspirin in vivo by measuring the target engagement of aspirin directly by MS. We developed a novel assay of cyclooxygenase-1 (COX-1) acetylation in platelets isolated from volunteers who were administered aspirin and used conventional and microfluidic assays to evaluate platelet function.	Celecoxib	102-111	prostaglandin-endoperoxide synthase 1	Homo sapiens	276-281	
25898179-9	2015	Pharmacological targeting of cyclooxygenase-1 and -2 (COX-1 and -2) using the nonselective inhibitor indomethacin, COX-1 inhibitor SC-560, and COX-2 inhibitor celecoxib revealed a contribution of COX-2 activity to the NMDA receptor"s downstream signaling events affecting BCRP.	Celecoxib	159-168	prostaglandin-endoperoxide synthase 1	Homo sapiens	29-52